bluebird bio, Inc. (NASDAQ:BLUE) had its price target hoisted by BMO Capital Markets in a research report sent to investors on Thursday, August 31st. The brokerage currently has an outperform rating on the biotechnology company’s stock.
Several other equities analysts also recently weighed in on the stock. Evercore ISI assumed coverage on shares of bluebird bio in a research note on Wednesday, August 16th. They issued an in-line rating and a $102.00 target price for the company. Jefferies Group LLC reaffirmed a buy rating and set a $88.00 price objective on shares of bluebird bio in a research note on Friday, August 11th. Morgan Stanley reaffirmed a hold rating on shares of bluebird bio in a research note on Wednesday, August 9th. BidaskClub raised shares of bluebird bio from a sell rating to a hold rating in a research note on Wednesday, August 9th. Finally, Sanford C. Bernstein assumed coverage on shares of bluebird bio in a research note on Thursday, July 27th. They set a market perform rating and a $109.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $107.86.
Shares of bluebird bio (NASDAQ:BLUE) opened at 131.85 on Thursday. bluebird bio has a 12 month low of $37.05 and a 12 month high of $136.85. The firm’s market cap is $6.01 billion. The stock’s 50 day moving average price is $105.28 and its 200-day moving average price is $96.03.
bluebird bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.66) by ($0.07). The business had revenue of $16.70 million during the quarter, compared to analysts’ expectations of $6.29 million. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. bluebird bio’s revenue for the quarter was up 977.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.59) EPS. Equities research analysts anticipate that bluebird bio will post ($6.84) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “bluebird bio, Inc. (NASDAQ:BLUE) Price Target Raised to $0.00 at BMO Capital Markets” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://ledgergazette.com/2017/09/15/bluebird-bio-inc-nasdaqblue-price-target-raised-to-0-00.html.
In other news, Director Daniel Lynch sold 4,000 shares of the company’s stock in a transaction dated Friday, June 23rd. The shares were sold at an average price of $109.09, for a total value of $436,360.00. Following the sale, the director now directly owns 4,808 shares of the company’s stock, valued at approximately $524,504.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mark Vachon sold 6,000 shares of the company’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $126.82, for a total transaction of $760,920.00. Following the completion of the sale, the director now directly owns 8,000 shares in the company, valued at $1,014,560. The disclosure for this sale can be found here. Over the last three months, insiders have sold 153,248 shares of company stock worth $17,708,425. Insiders own 3.90% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. QS Investors LLC grew its position in shares of bluebird bio by 70.7% in the 2nd quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after buying an additional 500 shares during the period. Bank of Montreal Can boosted its stake in bluebird bio by 118.9% in the 2nd quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 911 shares in the last quarter. Turner Investments LLC bought a new position in bluebird bio in the 2nd quarter worth about $184,000. SG Americas Securities LLC lifted its stake in bluebird bio by 17.9% during the 2nd quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 295 shares during the period. Finally, Fairfield Bush & CO. bought a new position in bluebird bio during the 2nd quarter valued at about $210,000.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for bluebird bio Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.